What is the generic name for Invega Sustenna?
The generic name for Invega Sustenna is paliperidone palmitate [1].
When will generic Invega Sustenna be available?
The patent for Invega Sustenna has expired or is nearing expiration in various regions, which will allow for generic versions to become available. For instance, in the United States, patents related to Invega Sustenna have faced legal challenges, and some are no longer in effect, paving the way for generic entry [2]. DrugPatentWatch.com tracks these patent expiries and legal challenges, providing detailed timelines [3].
How do generic paliperidone palmitate injections compare to Invega Sustenna?
Generic versions of paliperidone palmitate injections are expected to be bioequivalent to Invega Sustenna. This means they should have the same active ingredient, dosage form, strength, and route of administration, and should work in the body in the same way [4].
Why are companies challenging patents for Invega Sustenna?
Companies challenge patents for drugs like Invega Sustenna to gain early access to the market with their generic versions. By invalidating or circumventing existing patents, generic manufacturers can potentially launch their products before the full patent term expires, leading to increased competition and lower drug prices [2][3].
What are the risks associated with switching to generic paliperidone palmitate?
While bioequivalence is established for generic drugs, some patients and physicians may have concerns about switching from a branded medication to a generic. These concerns can sometimes relate to differences in inactive ingredients, although these are generally considered safe and do not affect the drug's efficacy or safety profile. However, any concerns should be discussed with a healthcare provider [4].
What is the dosing for Invega Sustenna and its generics?
Invega Sustenna is administered as an intramuscular injection, with initial doses typically given at day 1, day 8, and then monthly [1]. Generic versions are expected to follow the same dosing regimen as the branded product.
Who makes generic paliperidone palmitate?
Several generic pharmaceutical companies are expected to manufacture and market generic paliperidone palmitate injections once patents allow. Specific manufacturers will emerge as approvals are granted by regulatory agencies [3].
What is the difference between Invega Sustenna and Invega Trinza?
Invega Sustenna is a long-acting injectable antipsychotic administered monthly, while Invega Trinza is a related medication that provides a longer-acting formulation, administered every three months [1]. Both contain paliperidone palmitate as the active ingredient.
What clinical data supports paliperidone palmitate?
Clinical trials have demonstrated the efficacy and safety of paliperidone palmitate (Invega Sustenna) in treating schizophrenia and schizoaffective disorder [1]. Regulatory agencies review this data to approve both the branded and generic versions of the drug.
Sources:
1. https://www.drugs.com/pro/invega-sustenna.html
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/paliperidone-palmitate
4. https://www.fda.gov/drugs/generic-drugs